(S)-1-(2-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one | 1445704-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-1-(2-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
• 英文别名: 1-[(2S)-2-[[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
• CAS: 1445704-57-3
• 化学式: C₁₇H₂₂ClN₇O
• 分子量: 375.861
• InChiKey: PSVYKMBUIKACRQ-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  88
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE-2,4-DIAMINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：CELLZOME LTD

  公开号：WO2013092854A1

  公开（公告）日：2013-06-27

  The present invention relates to compounds of formula (I) wherein X, R, Y0, T0A, T0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compositions including said compoundsand their use as medicaments.

  本发明涉及式(I)的化合物，其中X、R、Y0、T0A、T0B的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫学介导的疾病。该发明还涉及包括所述化合物的药物组合物及其作为药物的用途。
• PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Cellzome Limited

  公开号：US20150005281A1

  公开（公告）日：2015-01-01

  The present invention relates to compounds of formula (I) wherein X, R, Y 0 , T 0A , T 0B have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds and their use as medicaments.

  本发明涉及式(I)的化合物，其中X，R，Y0，T0A，T0B的含义如所述和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导的疾病。本发明还涉及包括所述化合物的制药组合物及其作为药物的用途。